A new consensus statement in The Lancet Diabetes & Endocrinology describes GLP-1 receptor agonists as having “transformed obesity management, producing substantial weight loss and cardiometabolic benefits.” The GLP-1 prescription guidelines accompanying that endorsement are now generating debate about whether they help doctors treat more patients or quietly discourage them from trying.
The statement, published in 2026 by the European Association for the Study of Obesity (EASO), the European Federation of the Associations of Dietitians (EFAD), and the European Coalition for People Living with Obesity (ECPO), runs through an extensive set of recommendations for how clinicians should manage patients on GLP-1 medications. The stated goal is better, safer, more individualized care. Some clinicians reading it have come away with a different impression: that prescribing these drugs now requires a level of specialist infrastructure that most busy family doctors simply don’t have.
That tension sits at the center of a growing conversation in obesity medicine – one with real consequences for patients already struggling to access these drugs. GLP-1 prescription guidelines are multiplying as the medications become more powerful and more widely used. The question is whether that accumulation of guidance strengthens care or creates one more hurdle in a field already defined by hurdles.
What the New Guidance Actually Says
The EASO-EFAD-ECPO consensus statement outlines pragmatic nutritional, functional, and psychological considerations during incretin-based therapy treatment. Reduced appetite, rapid weight loss, gastrointestinal side effects, and changes in eating behavior can create nutritional, functional, or psychological risks in some individuals – and the guidance is designed to help clinicians anticipate and manage those risks.
The joint statement covers medical nutrition therapy delivered by a registered dietitian, including reinforcing healthy dietary patterns and facilitating long-term behavior change, along with advice on protein, fiber, vitamin and mineral intake, and eating patterns to minimize gastrointestinal side effects. It also recommends screening for eating disorders and psychological distress, identifying patients at elevated risk for nutritional deficiency, and monitoring body composition over time. To monitor body composition and functional status, the consensus statement recommends moving beyond BMI alone by incorporating central adiposity measures such as waist circumference or waist-to-height ratio, alongside a pragmatic measure of muscle function.
Much of this is sound clinical practice. Screening for eating disorders before prescribing a medication that suppresses appetite and causes rapid weight loss makes sense. So does encouraging adequate protein intake to preserve muscle mass during weight loss, or flagging patients at higher nutritional risk – such as older adults, those who have had bariatric surgery, or those with conditions that affect nutrient absorption.
The more contentious elements are the ones that require specialist involvement: personalized dietitian-led dietary assessment, individualized exercise prescriptions, DEXA scans (dual-energy X-ray absorptiometry, a detailed body composition scan), formal fitness testing, and professional psychological support to help patients adjust to changes in body image and food-related coping. These are genuinely valuable interventions. They are also, for most primary care practices, logistically out of reach – not because doctors don’t want to provide them, but because time, staffing, specialist availability, and patient finances make comprehensive multi-disciplinary care the exception, not the rule.
Where the GLP-1 Prescription Guidelines Criticism Comes From
Dr. Yoni Freedhoff, an associate professor of family medicine at the University of Ottawa and founder of the Bariatric Medical Institute, writing in a commentary published by Medscape on August 13, 2026, raised the concern that guidelines built around an idealized care model can discourage prescribing in primary care settings. When prescribing a medication becomes formally associated with a checklist that requires dietitian referral, psychological evaluation, body composition scanning, and individualized exercise programming, a clinician without those resources may reasonably conclude that they’re not equipped to prescribe at all – even when the evidence clearly supports doing so.
Obesity drug coverage in Medicaid remains limited, with only 13 state Medicaid programs covering GLP-1s for obesity treatment under fee-for-service as of January 2026. At the 2026 AMA Annual Meeting in Chicago, the House of Delegates adopted new policy to encourage the use of GLP-1 receptor agonists in accordance with evidence-based clinical indications within comprehensive care plans, and to encourage prescribers to evaluate individuals for body-image concerns, weight history, and eating disorders prior to prescribing. The AMA’s framing supports pre-prescribing evaluation within the goal of expanding access, not restricting it.
The AMA’s new policies call for legislation requiring public and private insurers to cover GLP-1 medications for obesity and type 2 diabetes at affordable prices, appropriate screening for eating disorders and weight history before prescribing, and greater pricing transparency and cost-control measures among drug manufacturers, insurers, and policymakers. The contrast with a framework that requires specialist co-management before a prescription is written reflects a genuine philosophical divide about where clinical standards should sit.
Safety and quality concerns behind the consensus statement are legitimate. In the SURMOUNT-5 trial at 72 weeks, tirzepatide achieved 20.2% mean weight loss and semaglutide achieved 13.7%, according to data published in the New England Journal of Medicine. Patients achieving weight loss at this scale face real risks of nutritional deficiency, muscle loss, and psychosocial disruption. The argument is that an overly detailed ideal may crowd out a workable standard, and that the absence of a realistic, stripped-down baseline for primary care prescribers leaves a gap that ultimately hurts patients.
The Access Problem Is Already Severe
GLP-1 access barriers are systemic and substantial before clinical complexity is added to the equation. Insurance coverage is a particular problem. Plans that cover these medications typically impose substantial prior authorization requirements, and some insurers have moved to restrict access or drop coverage entirely. Prior authorization for GLP-1 diabetes medications on Medicare increased from 5% or fewer beneficiaries requiring it before 2024 to nearly 100% by 2025, according to research from the University of Pennsylvania’s Leonard Davis Institute of Health Economics. These barriers have contributed to prescriber hesitation and real-world adherence rates far below those reported in clinical trials.
Medicare coverage presents a specific structural challenge. Under federal law, Medicare Part D plans cannot cover medications prescribed solely for weight loss. In response, the Centers for Medicare and Medicaid Services launched the Medicare GLP-1 Bridge Program in July 2026 as a temporary demonstration to provide eligible beneficiaries access to weight-loss medications outside standard Part D coverage. Eligible Medicare Part D enrollees can access specified GLP-1 products for obesity at a capped out-of-pocket cost of approximately $50 per month through the end of 2027.
Read More: Is This the “Ozempic of Alcohol”? the $2-a-Pill Drug That Can Reduce Drinking
The Risk of Good Intentions
The WHO issued its first global guideline on GLP-1 therapies for obesity in December 2025, recommending intensive behavioral therapy as a co-intervention when prescribing GLP-1 receptor agonists and GIP/GLP-1 dual agonists for obesity, within a chronic care model designed for long-term management. The WHO’s framing is explicitly about supporting, not replacing, clinical judgment.
The EASO-EFAD-ECPO consensus statement shares that goal. Dr. Laurence Dobbie, an academic clinical fellow in general practice at King’s College London’s Department of Population Health Sciences and lead author of the statement, developed the document with an international team of 26 authors. The statement is the first joint European consensus guidance to bring nutrition, function, and psychology together within a practical framework for incretin-based therapies. Guidelines, once published, shape prescribing culture – and in primary care, a framework built around specialist resources can read less like an aspiration and more like a requirement.
There is also an equity dimension to monitoring requirements that compounds payer-level access problems. The AMA’s new policy supports equitable access to comprehensive obesity care, including disease management services, nutritional therapies, health promotion initiatives, and prevention interventions for patients with obesity and individuals at elevated risk. If comprehensive care requirements become an informal prerequisite for prescribing, the patients least likely to have access to dietitians, exercise specialists, and mental health professionals – those with lower incomes, in rural areas, or without robust insurance – are also the most likely to be denied treatment.
Cost and insurance coverage remain the most significant practical barriers to initiating GLP-1 therapy. Adding clinical complexity to that landscape without a clear, simplified baseline for community prescribers risks making the gap wider. The EASO-EFAD-ECPO guidance is clinically sensible in many respects. The concern is that a document built around an ideal has not been paired with a minimum – a practical floor for what a competent primary care prescriber can do without specialist support, with a clear description of which patients genuinely need more. Without that floor, the ideal risks functioning as a barrier.
What This Means for You
If you or someone you care for has obesity and is considering GLP-1 medications, the clinical landscape is more favorable than ever – but the access landscape remains genuinely complicated. GLP-1 medications act on hunger-regulating regions of the brain, slow gastric emptying, and suppress appetite while promoting satiety signaling. The evidence base for their use in obesity continues to grow, and governing bodies from the WHO to the AMA have affirmed their place in long-term chronic disease management.
The practical steps that matter most right now: talk to your primary care doctor directly about whether you’re a candidate, ask specifically about insurance coverage and prior authorization, and don’t assume that a denial means the conversation is over. The AMA is actively advocating for legislation requiring public and private health insurers to provide GLP-1 receptor agonists for the treatment of type 2 diabetes and obesity at affordable formulary pricing, which would reduce out-of-pocket costs for patients.
The intent behind more detailed prescribing guidance is to improve safety and the quality of care, not to complicate prescribing for its own sake. Appropriate screening for eating disorders, realistic counseling on what to expect, and protein and fiber targets during weight loss are things most patients benefit from knowing. The question for clinicians and guideline authors alike is how to deliver that standard of care without turning the prescription pad into a specialist referral form.
Disclaimer: The author is not a licensed medical professional. The information provided is for general informational and educational purposes only and is based on research from publicly available, reputable sources. It is not intended to constitute, and should not be relied upon as, medical advice, diagnosis, or treatment. Always consult a licensed physician or other qualified healthcare provider regarding any medical condition, symptoms, or medications. Do not disregard, avoid, or delay seeking professional medical advice or treatment because of information contained herein.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.
Read More: GLP-1 Drugs May Cut Cancer Risk — And Not Just Because of Weight Loss